Seeking Alpha

Celgene (CELG -1%) slips after posting a lackluster Q4 report, with earnings matching analyst...

Celgene (CELG -1%) slips after posting a lackluster Q4 report, with earnings matching analyst expectations while revenue falls just short of estimates. The company reaffirms its FY13 outlook with revenue just shy of expectations, expecting to earn between $5.50 to $5.60 a share with 11% sales growth on around $6B in sales. The Street is looking for an EPS of $5.64 on $6.1B in revenue.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (4)
  • zorro2828
    , contributor
    Comments (655) | Send Message
     
    Just a monster.. cash machine... Just bought more this morning.. see you at $120.00
    24 Jan 2013, 02:40 PM Reply Like
  • 68jcode833RR
    , contributor
    Comments (5) | Send Message
     
    "Lackluster"??? You've got to be kidding me! Fourth quarter 2012 earnings (excluding special items but including stock-based compensation expense) beat the year-ago earnings by 26.9%.
    Total revenue climbed 12.7% to $1.45 billion in the fourth quarter of 2012. Net product sales climbed 13.9% to $1.42 billion.

     

    Net sales of Revlimid, the key growth driver at Celgene, came in at $1 billion, reflecting an increase of 17% over the year-ago period.

     

    Name any other company with that type of growth, 95% gross margins and a 16.5% overall tax rate. Lackluster? I think not! There's a WHOLE LOTTA LUSTER there!
    24 Jan 2013, 05:09 PM Reply Like
  • zorro2828
    , contributor
    Comments (655) | Send Message
     
    I trust you are well rewarded for being, like myself.. so bullish on this BRUTE.. There was so much LUSTER, that I bought a pant load!
    25 Jan 2013, 08:33 AM Reply Like
  • 68jcode833RR
    , contributor
    Comments (5) | Send Message
     
    I've been overweight CELG for quite a while. It's been a stock that has required considerable patience. On fundamentals and outlook, there may be no stronger company in the S&P 500. The company has excellent leadership, an incredible CFO Jackie Fouse, and a product pipeline that is the envy of all biotech and pharma. Game changing Abraxane results in pancreatic cancer are being presented this afternoon. Pomalidimide is on the brink of approval. Apremilast is showing exceptional results in psoriasis. Product diversification is more evident every month and with every presentation. CELG can no longer be criticized as a one trick pony with Thalidomide/Revlimid. I realize I'm preaching to the choir but, it's a story that should be told and hopefully a few other eyes will see this.
    25 Jan 2013, 11:30 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs